Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana

This article was originally published in The Pink Sheet Daily

Executive Summary

New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.

You may also be interested in...

CTI Bags Cash, Turns Its Back On Zevalin

Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.

J&J Advances Pipeline With Yondelis, Carisbamate Filings

Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.

Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition

Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts